COPENHAGEN, Denmark, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP, Financial) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the LSX Nordic Congress being held August 29-30, 2018 in Stockholm, Sweden. Dr. Svendsen will present a corporate update on Thursday, August 30, 2018 at 15.15 CET and will be available for one-on-one meetings. A recording of the presentation will be made available through the Company’s website.
About Forward Pharma:
Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on net sales of Tecfidera® or other DMF products for MS on a country-by-country basis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the EP2801355 Opposition Proceedings, including any appeals.
The principal executive offices are located at Østergade 24A, 1st Floor, 1100 Copenhagen K, Denmark and our American Depositary Shares are publicly traded on the Nasdaq Stock Market (FWP, Financial). For more information about the Company, please visit our website at http://www.forward-pharma.com.
Forward Pharma A/S Investor Relations Contact:
Forward Pharma A/S
Claus Bo Svendsen, MD, PhD
Chief Executive Officer
Investor Relations
[email protected]
Solebury Trout
John Graziano
[email protected]
+1 (646) 378 2942
